{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T15:12:24Z","timestamp":1772637144900,"version":"3.50.1"},"reference-count":19,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Cardiac involvement in patients with systemic sclerosis (SSc) can present variably from being asymptomatic to manifesting with heart failure, conduction abnormalities, pulmonary hypertension, and pericardial effusion. Symptomatic cardiac involvement portends a poor prognosis and worse overall survival. Sacubitril\/valsartan (SV), an angiotensin receptor neprilysin inhibitor, has been shown to significantly reduce hospitalization rates and morbidity in patients with heart failure with reduced ejection fraction (HFrEF). This study aimed to investigate the effects of SV treatment in patients with SSc and heart failure. Methods: A retrospective analysis of patients with SSc was conducted using an electronic data capture tool. Patients with SSc treated with SV between January 2015 and August 2023 were identified. Comprehensive clinical phenotyping and longitudinal data analysis were performed to characterize the sub-type of patients and evaluate clinical outcomes, including hospitalizations and mortality, laboratory markers, and echocardiographic findings. Results: Twenty-four patients with SSc were treated with SV for a mean duration of 20.6 months. HFrEF was the primary indication for SV use in 91% of patients, primarily due to non-ischemic cardiomyopathy (87.5%). There was a significant reduction in systolic blood pressure from 128 mmHg to 114 mmHg (p &lt; 0.001) and NT-proBNP levels from 15,130 pg\/mL to 5082 pg\/mL (p = 0.046). In the 19 patients with baseline and follow-up echocardiograms, there was a significant improvement in LVEF from 40.3% to 47.7% (p = 0.014). Hypotension was a common side effect leading to discontinuation of SV (n = 4, 16.7%). Serum creatinine had trends of improvement (1.9 mg\/dL to 1.3 mg\/d), though it did not reach statistical significance (p = 0.057). Conclusions: This study showed that SV effectively improved cardiac symptoms and function in patients with SSc presenting with HFrEF. Further prospective studies are needed to confirm these findings and explore the role of SV in the treatment of other manifestations of SSc.<\/jats:p>","DOI":"10.3390\/jcm14124054","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T05:54:05Z","timestamp":1749448445000},"page":"4054","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Effectiveness of Sacubitril\/Valsartan in Systemic Sclerosis Patients with Heart Failure: A Retrospective Analysis"],"prefix":"10.3390","volume":"14","author":[{"given":"Nouran","family":"Eshak","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Abdelnabi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7595-7630","authenticated-orcid":false,"given":"Jaxon","family":"Quillen","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Mayo Clinic, Scottsdale, AZ 85259, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micheal","family":"Pham","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Hentz","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Mayo Clinic, Scottsdale, AZ 85259, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Nagaraja","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jaad.2021.10.065","article-title":"Systemic sclerosis in adults. Part I: Clinical features and pathogenesis","volume":"87","author":"Jerjen","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/BOR.0000000000001038","article-title":"Heart involvement in systemic sclerosis: Emerging concepts","volume":"36","author":"Fairley","year":"2024","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s00296-024-05699-x","article-title":"Heart involvement in patients with systemic sclerosis\u2014What have we learned about it in the last 5 years","volume":"44","author":"Nadel","year":"2024","journal-title":"Rheumatol. Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/1744666X.2023.2171988","article-title":"Understanding and managing cardiac involvement in systemic sclerosis","volume":"19","author":"Moysidou","year":"2023","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1093\/rheumatology\/kead599","article-title":"Heart and systemic sclerosis\u2014Findings from a national cohort study","volume":"63","author":"Carrat","year":"2024","journal-title":"Rheumatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/1346-8138.14162","article-title":"Diagnostic criteria, severity classification and guidelines of systemic sclerosis","volume":"45","author":"Asano","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/ehjci\/jead147","article-title":"The primary cardiomyopathy of systemic sclerosis on cardiovascular magnetic resonance imaging","volume":"24","author":"Chhikara","year":"2023","journal-title":"Eur. Heart J.-Cardiovasc. Imaging"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e036730","DOI":"10.1161\/JAHA.124.036730","article-title":"Evaluation of systemic sclerosis primary heart involvement and chronic heart failure in the European scleroderma trials and research cohort","volume":"14","author":"Filla","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/ehjci\/jeac094","article-title":"Diffuse myocardial fibrosis precedes subclinical functional myocardial impairment and provides prognostic information in systemic sclerosis","volume":"24","author":"Gotschy","year":"2023","journal-title":"Eur. Heart J.-Cardiovasc. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"176170","DOI":"10.1016\/j.ejphar.2023.176170","article-title":"Sacubitril\/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction","volume":"961","author":"Shi","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"111963","DOI":"10.1016\/j.intimp.2024.111963","article-title":"Sacubitril\/valsartan alleviates sunitinib-induced cardiac fibrosis and oxidative stress via improving TXNIP\/TRX system and downregulation of NF-\u0138B\/Wnt\/\u03b2-catenin\/SOX9 signaling","volume":"132","author":"Mohamad","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mustafa, N.H., Jalil, J., Zainalabidin, S., Saleh, M.S., Asmadi, A.Y., and Kamisah, Y. (2022). Molecular mechanisms of sacubitril\/valsartan in cardiac remodeling. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.892460"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13023-023-02699-1","article-title":"The clinical characteristics and outcomes of patients with systemic sclerosis with myocardial involvement","volume":"18","author":"He","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro\u2013B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"Jama"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.15420\/cfr.2016:1:1","article-title":"The mechanism of action of LCZ696","volume":"2","author":"Menendez","year":"2016","journal-title":"Card. Fail. Rev."},{"key":"ref_17","first-page":"431","article-title":"Assessment of sacubitril\/valsartan effects on left ventricular dynamics using 3D echocardiography and 3D strain in heart failure with reduced ejection fraction patients","volume":"70","author":"Abdelnabi","year":"2021","journal-title":"Minerva Cardiol. Angiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/ehf2.13952","article-title":"Sacubitril\/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension","volume":"9","author":"Codina","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1002\/ehf2.13002","article-title":"Effect of sacubitril\/valsartan on renal function: A systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Spannella","year":"2020","journal-title":"ESC Heart Fail."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/12\/4054\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:48:28Z","timestamp":1760032108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/12\/4054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,8]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["jcm14124054"],"URL":"https:\/\/doi.org\/10.3390\/jcm14124054","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,8]]}}}